81 studies found for:    hedgehog
Show Display Options
Rank Status Study
1 Recruiting Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Conditions: Histologically Confirmed Medulloblastoma;   Activation of the Sonic Hedgehog (SHH) Pathway
Interventions: Drug: vismodegib;   Drug: Temozolomide
2 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib;   Drug: Bevacizumab;   Drug: Modified FOLFOX;   Drug: FOLFIRI
3 Terminated Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)
Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: GDC-0449
4 Not yet recruiting Ribavirin and Hedgehog Inhibitor With or Without Azacytidine in AML
Condition: Acute Myeloid Leukemia
Interventions: Drug: Ribavirin;   Drug: Hedgehog inhibitor;   Drug: Azacytidine
5 Not yet recruiting LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A Cirrhosis
Conditions: Hepatocellular Carcinoma;   Cirrhosis
Intervention: Drug: LDE225
6 Recruiting Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Gemcitabine, nab-Paclitaxel, GDC-0449
7 Not yet recruiting Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis
Conditions: Arthritis, Rheumatoid;   Neovascularization, Pathologic;   Synovitis
Intervention:
8 Active, not recruiting The Purpose of This Study is to Determine The Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
Conditions: Basal Cell Nevus Syndrome;   Gorlin Syndrome
Intervention: Drug: GDC-0449
9 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Condition: Ovarian Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib
10 Completed A Study Of PF-04449913 Administered Alone In Select Solid Tumors
Condition: Solid Tumors
Intervention: Drug: PF-04449913
11 Recruiting Interrogation of Wnt, Notch and Hedgehog Activity in Primary Tumor Samples
Condition: Cancer
Intervention:
12 Completed A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Condition: Solid Cancers
Intervention: Drug: GDC-0449
13 Completed A Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-Sponsored Phase I or II Cancer Study
Condition: Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab;   Drug: FOLFIRI;   Drug: FOLFOX;   Drug: GDC-0449
14 Recruiting A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer
Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: LDE225
15 Recruiting PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
Intervention: Drug: Hedgehog inhibitor PF-04449913
16 Recruiting Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Condition: Resectable Pancreatic Adenocarcinoma
Interventions: Drug: LDE-225;   Drug: Gemcitabine;   Drug: nab-paclitaxel
17 Active, not recruiting Leuprolide Acetate or Goserelin With or Without GDC-0449 Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Drug: leuprolide acetate;   Drug: goserelin acetate;   Drug: vismodegib
18 Not yet recruiting Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer
Condition: Pancreatic Adenocarcinoma Resectable
Interventions: Drug: gemcitabine;   Drug: Vismodegib;   Procedure: Neoadjuvant chemotherapy
19 Recruiting A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Condition: Acute Myeloid Leukemia
Interventions: Drug: PF-04449913;   Drug: Low dose ARA-C (LDAC);   Drug: Decitabine;   Drug: Daunorubicin;   Drug: Cytarabine;   Drug: Pf-04449913
20 Completed A Study Of PF-04449913 In Select Hematologic Malignancies
Condition: Hematologic Malignancies
Intervention: Drug: PF-04449913

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years